Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Durham, North Carolina

This page shows live ClinicalTrials.gov search results for Durham, North Carolina, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1196
Shown on this page
12
Current sort
Recently updated
Location scope
Durham, NC
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Durham, North Carolina. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 529–540 of 1,196 matching trials in Durham, NC.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Durham

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Completed Phase 3 Interventional Results available

Immune Modulators for Treating COVID-19

NCT04593940
View directory record Official record
Conditions
Covid19
Interventions
Infliximab, Abatacept, Remdesivir, cenicriviroc (closed to enrollment as of 3-Sep-2021)
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
18 Years and older
Enrollment
1,971 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
67
States / cities
Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 54 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Nov 7, 2026, 11:56 AM EST
Not listed No phase listed Observational

Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical Trial

NCT01004640
View directory record Official record
Conditions
Leukemia
Interventions
DNA analysis, Southern blotting, cytogenetic analysis, polymerase chain reaction
Genetic
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
161
States / cities
San Diego, California • San Francisco, California • Lewes, Delaware + 89 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Nov 7, 2026, 11:56 AM EST
Active, not recruiting No phase listed Observational

Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia

NCT00003861
View directory record Official record
Conditions
Leukemia, Acute Lymphoblastic Leukemia, Acute Promyelocytic Leukemia
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
51
States / cities
San Diego, California • San Francisco, California • Lewes, Delaware + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Nov 7, 2026, 11:56 AM EST
Terminated Phase 2 Interventional Results available

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

NCT03606174
View directory record Official record
Conditions
Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Ureter, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Urethra
Interventions
Sitravatinib, Nivolumab, Pembrolizumab, Enfortumab vedotin
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
36
States / cities
Tucson, Arizona • Irvine, California • Aurora, Colorado + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Nov 7, 2026, 11:56 AM EST
Completed Phase 2 Interventional

Video-Assisted Surgery in Treating Patients With Non-small Cell Lung Cancer

NCT00003692
View directory record Official record
Conditions
Lung Cancer
Interventions
therapeutic thoracoscopy, video-assisted surgery
Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
112
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 72 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Nov 7, 2026, 11:56 AM EST
Completed Phase 2 Interventional Results available

A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer

NCT02614794
View directory record Official record
Conditions
HER2 Positive Breast Cancer
Interventions
tucatinib, capecitabine, trastuzumab, placebo
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
81
States / cities
Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Nov 7, 2026, 11:56 AM EST
Completed No phase listed Observational

Risk-Group Classification of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT00482352
View directory record Official record
Conditions
Untreated Adult Acute Lymphoblastic Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 30 Years
Enrollment
11,196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2023
U.S. locations
176
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 141 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Nov 7, 2026, 11:56 AM EST
Completed Phase 3 Interventional

Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor

NCT00006734
View directory record Official record
Conditions
Sarcoma
Interventions
filgrastim, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, vincristine sulfate, adjuvant therapy, conventional surgery, neoadjuvant therapy, brachytherapy, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
0 Years to 50 Years
Enrollment
587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2023
U.S. locations
212
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 155 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Nov 7, 2026, 11:56 AM EST
No Longer Available No phase listed Expanded access

Expanded Access to Voxelotor for Patients With Sickle Cell Disease Who Have No Alternative Treatment Options

NCT03943615
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Voxelotor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
18
States / cities
Birmingham, Alabama • Mobile, Alabama • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Nov 7, 2026, 11:56 AM EST
Completed No phase listed Observational Results available

Multi-center Prospective Study to Evaluate Outcomes of the Moderate to Severely Calcified Coronary Lesions (MACE)

NCT01930214
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Percutaneous Coronary Intervention
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
34
States / cities
Little Rock, Arkansas • Glendale, California • Hartford, Connecticut + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Nov 7, 2026, 11:56 AM EST
Completed Phase 3 Interventional Results available

Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis

NCT03434028
View directory record Official record
Conditions
Septic Shock
Interventions
Early Vasopressors, Early Fluids
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
1,563 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
50
States / cities
Tucson, Arizona • Fresno, California • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Nov 7, 2026, 11:56 AM EST
Completed Phase 4 Interventional Results available

Surveillance Trial to Evaluate a Shortened Infusion Time of Intravenous Ibuprofen

NCT01334944
View directory record Official record
Conditions
Pain, Fever
Interventions
Intravenous ibuprofen
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
13
States / cities
San Diego, California • Danbury, Connecticut • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Nov 7, 2026, 11:56 AM EST